









Markets
/
Stocks
/
nasdaq-nmra
/

Neumora Therapeutics Inc

NMRA

View Detailed Chart

1.650USD

+0.090+5.78%

Market hours （ET）Quotes delayed by 15 min

266.90MMarket Cap

LossP/E TTM



Neumora Therapeutics Inc

1.650

+0.090+5.78%

Overview Company Financials

Financials

Intraday

30m

Today

+5.78%

5 Days

-29.78%

1 Month

+100.84%

6 Months

-11.28%

Year to Date

-84.43%

1 Year

-86.81%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 8 analysts

HOLD

Current Rating

7.000

Target Price

348.72%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

552

Total

Median

Average

Company name

Ratings

Analysts

Neumora Therapeutics Inc

NMRA

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Ionis Pharmaceuticals Inc

IONS

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Neutral

Sell(5)

Neutral(3)

Buy(3)

Indicators

Sell(1)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.047

Neutral

RSI(14)

49.368

Neutral

STOCH(KDJ)(9,3,3)

19.251

Sell

ATR(14)

0.319

High Vlolatility

CCI(14)

-70.297

Neutral

Williams %R

80.625

Oversold

TRIX(12,20)

4.115

Buy

StochRSI(14)

0.000

Oversold

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

2.014

Sell

MA10

2.041

Sell

MA20

1.663

Sell

MA50

1.148

Buy

MA100

1.005

Buy

MA200

4.110

Sell

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company’s therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Its other candidates include NMRA-266, NMRA-511, and NMRA-NMDA. NMRA-266 is a positive allosteric modulator program of the M4 muscarinic receptor (M4R) for the treatment of schizophrenia. NMRA-266 is designed to be selective for the M4 receptor subtype of the muscarinic receptor family. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR). NMRA-NMDA is an NMDA positive allosteric modulator program that the Company is developing for the treatment of schizophrenia.

Ticker SymbolNMRA

CompanyNeumora Therapeutics Inc

CEOMr. Paul L. Berns

Websitehttps://neumoratx.com/